What does 'the body as a bioreactor' mean? In this discussion how scientists use the body's machinery to produce therapeutic proteins. Scott Ripley, General Manager of Nucleic Acids at Cytiva, explains that traditional bioprocessing uses external bioreactors, while the new approach leverages the body's natural processes. This method offers benefits like longer protein half-life and the ability to express multiple proteins simultaneously. Justin Eyquem, assistant professor at University of California San Francisco, discusses the potential of in vivo CAR T cell therapy, which could simplify manufacturing and reduce costs. Both approaches face challenges in quality assurance and regulatory approval but hold promise for personalized and more effective treatments.

We're diving into advanced therapies with industry leaders. Emmanuel Abate, President of Genomic Medicine at Cytiva discussed the strategies to accelerate clinical work and reduce costs. Nathaniel Wang, CEO and Co-Founder of Replicate Bioscience highlighted their ground breaking self-replicating RNA technology, showcasing impressive clinical results for a rabies vaccine. Both experts emphasized the momentum in biotech, the potential of AI in advancing science, and the importance of making innovative therapies accessible globally. Stay tuned for these insights.

Show notes

• Beneath Everest, a lone caretaker struggles to keep one of the world’s highest laboratories alive
• Integrating human endogenous retroviruses into transcriptome-wide association studies highlights novel risk factors for major psychiatric conditions

Keywords: vaccines, advanced therapies, mRNA, manufacturing, technology, patients, innovation, new modalities.

From gene and cell therapies, to the use of CRISPR and other precision engineering technologies, this episode dives into the opportunities and challenges of the emerging field of advanced therapies.

On Discovery Matters this week, Dodi and Conor are joined by Daria Donati, Chief Scientific Officer of Genomic Medicine at Cytiva, as well as Jen Moody, Vice President of External Innovation of Genomic Medicines at Danaher, to discuss the science, progress, and potential of advanced therapeutics.

Demaris Mills, Group Executive of Genomic Medicines at IDT, and experts Fyodor Urnov, Professor of Molecular and Cell Biology at the University of California, Berkeley, and the Director of Technology & Translation at the Innovative Genomics Institute, cover the technologies used in gene and cell therapies as well as CRISPR to deliver powerful and precise treatments aiming for a healthier future.

Can you tell the difference between a human and AI? Of course you can…right? We challenge Conor and Dodi to tell the difference between Conor and Conor BOT all while uncovering how AI is transforming the life sciences.

Uncover how AI is transforming the life sciences. Together with an AI-bot the pair explore the potential applications of AI in drug discovery, personalizing medical treatments, protein folding, and more. They also consider the ethical considerations required when developing AI models, as well as the need for emotional intelligence in AI systems.

Keywords: AI, ethical dilemma, bias, misinformation, datasets, diagnostics, drug discovery, healthcare.

Let's explore the remarkable colour-changing abilities of cephalopods. Joined by Dan Wilson from the Kostas Research Institute at Northeastern University, the team dive into the fascinating research behind the development of paints that respond to environmental stimuli, such as sunlight. They also discuss titanium dioxide and how it acts as a facilitator of the colour-changing process. Professor Alon Gorodetsky, Associate Professor of Chemical and Biomolecular Engineering at the University of California, Irvine, talks about his research on developing energy-responsive dyes to mimic the features of octopi. Discover the potential applications of these dyes from diagnostics to resource-constrained initiatives, and more. Listen in and discover this remarkable evolutionary adaptation and the incredible ingenuity of cephalopods.

In this episode of Discovery Matters, hosts Dodi and Conor explore how synthetic biology can lead to transformative breakthroughs when it comes to dealing with global health problems. Through their conversation with Justin Vigar, a PhD student in Dr. Keith Pardee's lab at the University of Toronto in Canada, we learn how his team's paper-based diagnostic tool has the potential to provide faster, more cost-efficient, and accessible diagnostics for underserved locations. This is complemented by Amir Pandi and Tobi Erb's discussion of using AI and synthetic biology to develop new antimicrobial peptides.

Show notes

• U of T PhD student uses synthetic biology to create low-cost diagnostic tools.

• Pandi, A., Adam, D., Zare, A. et al. Cell-free biosynthesis combined with deep learning accelerates de novo-development of antimicrobial peptides. Nat Commun 14, 7197 (2023). https://doi.org/10.1038/s41467-023-42434-9

• Khalek IS, et al. Synthetic development of a broadly neutralizing antibody against snake venom long-chain α-neurotoxins. Sci Transl Med. 2024 Feb 21;16(735). https://doi.org/10.1126/scitranslmed.adk1867

• Josh A Goldstein, Jason Chao, Shelby Grossman, Alex Stamos, Michael Tomz, How persuasive is AI-generated propaganda?, PNAS Nexus, Volume 3, Issue 2, February 2024. https://doi.org/10.1093/pnasnexus/pgae034

Tune in to Discovery Matters to see how we can drug the undruggable. Dodi and Conor talk to Mark Bray, a second year PhD student in the Bowman Lab at the University of Pennsylvania, about the concept of “drugging the undruggable” for drug discovery and development. They discuss advances in medical research which has enabled us to drug molecular targets that were previously inaccessible, and the strategies that are used to devise and find effective drugs. Vicky Richon, CEO at Entact Bio, elucidates the importance of a revolutionary “induced proximity” modality for unprecedented drug treatments. Listen to this episode to understand modern approaches to treating diseases and uncovering cures.

Explore the potential of artificial intelligence (AI) and machine learning to revolutionize biomedical research and make personalized healthcare a reality.

Tune in to Discovery Matters to see how AI and machine learning will be the future of biomedical research. Featuring interviews with Professor Kourosh Saeb-Parsy and Dr Namshik Han — leaders in the AI and biotech space — this episode delves into the significance of advanced technology for unlocking discoveries in transplantation, understanding the causes of diseases, precision medicine, and more.

Show notes:

This AI learnt language by seeing the world through a baby’s eyes

Computational phylogenetics reveal histories of sign languages